Emergence of a dominant cytotoxic T lymphocyte antitumor effector from tumor-infiltrating cells in the anterior chamber of the eye-Reference-Cited by-同舟云学术

Emergence of a dominant cytotoxic T lymphocyte antitumor effector from tumor-infiltrating cells in the anterior chamber of the eye

Published:1990-11 Issue:6 Volume:30 Page:323-330
ISSN:0340-7004
Container-title:Cancer Immunology Immunotherapy
language:en
Short-container-title:Cancer Immunol Immunother

Author:

Knisely Terrence L.,Niederkorn Jerry Y.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Immunology,Immunology and Allergy

Link

http://link.springer.com/content/pdf/10.1007/BF01786881.pdf

Reference61 articles.

1. Akiyama M, Bean MA, Sadamoto K, Takahashi Y, Brankovan V (1983) Suppression of the responsiveness of lymphocytes from cancer patients triggered by coculture with autologous tumor-derived cells. J Immunol 131: 3085

2. Austyn JM, Gordon S (1981) F4/80, a monoclonal antibody directed specifically against the mouse macrophage. Eur J Immunol 11: 805

3. Basham TY, Merigan TC (1983) Recombinant interferon-γ increases HLA-DR synthesis and expression. J Immunol 130: 1492

4. Beutler B, Cerami A (1987) Cachectin: more than a tumor necrosis factor. N Engl J Med 316: 379

5. Boon T, Van Snick J, Van Pel A, Uyttenhove C, Marchand M (1980) Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815 II. T lymphocyte-mediated cytolysis. J Exp Med 152: 1184

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic Implications of Novel Ten-Gene Signature in Uveal Melanoma;Frontiers in Oncology;2020-10-30

2. Immunobiology of Uveal Melanoma: State of the Art and Therapeutic Targets;Frontiers in Oncology;2019-11-05

3. IFN-γ-independent intraocular tumor rejection is mediated by a macrophage-dependent process that leaves the eye intact;Journal of Leukocyte Biology;2012-11

4. IL-17–Dependent, IFN-γ–Independent Tumor Rejection Is Mediated by Cytotoxic T Lymphocytes and Occurs at Extraocular Sites, but Is Excluded from the Eye;The Journal of Immunology;2011-09-14

5. Immune Privilege of Corneal Allografts;Ocular Immunology and Inflammation;2010-05-20